Rx (Prescription Medicine)
USD $ 120.00
USD $ 30.00 per injection
Bevazza 400mg Injection 是一种用于治疗特定类型癌症的靶向疗法药物。其活性成分为 Bevacizumab，一种重组人源化单克隆抗体。Bevacizumab 通过抑制血管内皮生长因子（VEGF）的活性发挥作用，VEGF 是一种促进新血管生成的蛋白质。通过阻断 VEGF，Bevazza 有助于使肿瘤缺血，从而减缓或停止其生长。它通常与化疗联合使用，用于治疗转移性结直肠癌、非鳞状非小细胞肺癌以及胶质母细胞瘤。Bevazza 400mg Injection 的给药剂量和使用方式应严格由合格的医疗专业人员根据具体的癌症类型、分期以及个体患者因素确定。常见的不良反应可能包括高血压、蛋白尿、鼻出血、疲劳以及伤口愈合延迟。在使用前需向医生报告任何既往疾病，尤其是心血管问题或近期手术史。Bevazza 400mg Injection 应储存在室温（20°C 至 25°C）并避光保存，禁止冷冻。如对用药或潜在的不良反应有任何疑虑，请咨询您的医疗提供者。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 400 mg |
| Medicine Form | Injection |
| Pack Quantity | 4 ML |
| Packaging Type | Vial / Bottle |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 400 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
